Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
|---|---|---|---|---|---|---|
| Hemlibra | emicizumab | Bleeding prevention, hemophilia A | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Forxiga | dapagliflozin | Heart failure with reduced ejection fraction | Reimburse with clinical criteria and/or conditions | Complete | ||
| Daurismo | Glasdegib | Acute Myeloid Leukemia (AML) | Do not reimburse | Complete | ||
| Calquence | Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Entyvio | vedolizumab | Crohn’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| pdp-levETIRAcetam | Levetiracetam | Epilepsy | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ofev | nintedanib | chronic fibrosing interstitial lung diseases | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024